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The export of proteins from the nucleus to the cytoplasm plays an important 
role in the development of cancer and drug resistance [1–3]. The major mammalian 
nuclear export receptor protein is exportin 1 (XPO1, also known as chromosomal 
maintenance 1/ CRM1/) [1–5]. The crystal structure of this protein showed a 
complex with the Ran protein (Ras-related nuclear protein) bound to GTP [6, 7]. 
XPO1 interacts also with nucleoporins in the nuclear pore complex and transports 
multiple tumor suppressor proteins (eg p53, FOXO, p21 pRB, BRCA1/2), growth 
regulators, and oncoprotein mRNAs (eg c-myc, Bcl-xL, MDM2, cyclins) containing 
a leucine rich nuclear export signal (NES) (Figure 1) [8]. XPO1 is also involved in 
regulation of cytoplasmic localization and translation of c-myc and other onco-
protein mRNAs (eg cyclin D1, Bcl-6, Mdm2, and Pim) through complexing with 
eukaryotic initiation factor 4E (eIF4E) [9]. The XPO1 protein level is increased 
in many types of cancer including multiple myeloma [10–13]. As a result of the 
increased nuclear-cytoplasmic transport in cancer cells, an elevated level of multi-
ple tumor suppressor proteins and oncoproteins in the cytoplasm leads to advanced 
disease, resistance to therapy, and poor survival. Thus, XPO1 is a promising cancer 
drug target. Leptomycin B (LMB) is a Streptomyces metabolite that inhibits the 
function of XPO1 in NES-dependent nuclear export of proteins [14]. However, 
clinical studies found serious side effects of LMB. In order to find a more specific 
inhibitor of XPO1 without side effects, many natural and synthetic compounds 
have been tested. These compounds include selinexor (KPT-330, XPOVIO™), 
verdinexor (KPT-335), KPT-185, KPT-276, KPT-251, and KPT-8602 [15–18]. These 
agents are a family of small molecules that block nuclear export through covalent 
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binding to cysteine 528 (Cys528) in the cargo proteins NES-binding pocket of 
exportin1 and contribute to cancer cell death [15]. All these drugs have been devel-
oped by Karyopharm Therapeutics Inc., Natick, MA.
Figure 1. 
Exportin 1-mediated nuclear export in multiple myeloma; Abbreviations: Ran-GDP and Ran-GTP – GDP 
or GTP bound Ras related factor; NPC – nuclear pore complex; SINE - selective inhibitor of nuclear 
export; FOXO – a subgroup of the Forkhead family of transcription factors, p53 – a tumor suppressor 
protein and transcription factor; XPO1 – exportin 1, also known as chromosomal maintenance 1 (CRM1); 
(A) XPO1 transports nuclear proteins out of the nucleus. Cargo proteins such as FOXO or p53 that are 
marked for export from the nucleus bind a pocket in XPO1 in the presence of the activated small G-protein, 
Ran. The active Ran-GTP-XPO1-cargo complex is exported from the nucleus through the nuclear pore 
complex driven by the concentration gradient of Ran-GTP across the nuclear membrane. Once in the 
cytoplasm, Ran-GTP is hydrolyzed to Ran-GDP, and the XPO1-cargo complex dissociates. (B) SINE 
compounds (Hexagons) bind to XPO1-Cys528 and occupy the cargo-binding pocket of XPO1 and prevent 
formation of the Ran-GTP-XPO1-cargo complex. The result is increased nuclear localization of tumor 
suppressor cargo proteins and upregulation of their transcriptional activity [15].
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2. Selinexor-a small molecule exportin 1 inhibitor
The structural formula of selinexor is shown in Figure 2. Selinexor is a first 
member of small molecule oral inhibitors of exportin 1 developed for the treatment 
of cancer. Selinexor in combination with a synthetic glucocorticoid dexamethasone 
was approved by the FDA (U.S. Food and Drug Administration) on July 3, 2019 
for the treatment of adult patients with relapsed or refractory multiple myeloma 
(RRMM) who have received at least four prior therapies. Selinexor synergizes 
with dexamethasone and inhibits the mTOR pathway and subsequently induces 
cell death in multiple myeloma cells [19]. Selinexor increases the expression of 
glucocorticoid receptor and in combination with dexamethasone stimulates 
transcriptional activity of the glucocoticoid receptor [19]. Selinexor is studied in 
clinical trials also in many hematological and solid cancers [20–24]. The treatment 
with selinexor in preclinical and clinical studies resulted in nuclear localization of 
tumor suppressor proteins (eg p53 and FOXO3A), induced apoptosis and decreased 
proliferation. Selinexor reduces the expression of DNA damage repair proteins and 
sensitizes cancer cells to DNA damaging agents [25]. Selinexor blocks the transcrip-
tion factor NF-κB and induces ribosomal stressby disruption of ribosomal subunits 
assembly [26].
Selinexor is orally bioavailable with a mean half-life 6–8 h after a single dose. 
Selinexor pharmacokinetics are not significantly affected by age, sex, ethnicity, 
renal impairment or mild hepatic impairment. Most frequent adverse events associ-
ated with selinexor treatment are thrombocytopenia, fatigue, nausea, anemia, 
decreased appetite, decreased weight, diarrhoea, vomiting, hyponatremia, neutro-
penia, leukopenia, constipation, dyspnoea, and upper respiratory tract infection.
3.  The phase II STORM trial with selinexor plus low-dose 
dexamethasone in patients with multiple myeloma pretreated 
with bortezomib, carfilzomib, lenalidomide, pomalidomide, 
daratumumab, and an alkylating agent
Selinexor demonstrated small single-agent activity with an overall response 
rate achieved in 4% (2/57 heavily pre-treated patients with RRMM (about six prior 
therapies)) [27]. The response was considerably increased from 4 to 50% (6/12) 
when selinexor was combined with dexamethasone in a phase I trial in patients with 
advanced hematological malignancies (NCT 01607892) [27]. The phase II STORM 
trial (NCT02336815) with selinexor and dexamethasone combination in heav-
ily pre-treated patients with RRMM had relatively quick responses. The primary 
Figure 2. 
Chemical structure of selinexor (alternative names: ATG-010, KPT-330, ONO7705, XPOVIO, CRM1 nuclear 
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endpoint was overall response. Patients were given twice weekly oral doses of 
selinexor (80 mg) and dexamethasone (20 mg) in 28-day cycles [28, 29]. An overall 
response was recorded in 21% patients (16/78) or 26% (32/122) and median dura-
tion of response was 5 months. Patients required a lot of supportive care to mange 
many side effects. The most common adverse event was thrombocytopenia.
4.  A multicenter, open-label, phase 1b/2, dose escalation trial STOMP in 
patients with relapsed or refractory multiple myeloma with a median 
of three prior therapies
The STOMP trial (NCT02343042) is a five arms study of selinexor, dexametha-
sone and either lenalidomide, pomalidomide, bortezomib, carfilzomib or daratu-
mumab for the treatment of relapsed or refractory multiple myeloma with median 
of three prior therapies in order to evaluate the safety, tolerability and efficacy of 
these combinations, determining the maximum tolerated dose, the recommended 
phase 2 dose, overall response rate (ORR), and progression-free survival (PFS) 
[23, 24, 26]. Individual arms were described in abstracts No. 726, 1366, and 1393 on 
ASH 2020 meeting.
5.  The randomized open-label, phase III international BOSTON trial in 
patients with relapsed or refractory multiple myeloma with a median 
of two prior therapies
The combination of selinexor and bortezomib once per week plus dexametha-
sone twice per week (SVd) was compared with bortezomib twice per week in 
combination with dexamethasone four times per week for the first six months and 
one half of this dose thereafter (Vd) [30]. Median PFS was longer with selinexor 
treatment: 13.93 months versus 9.46 months in the Vd group. The improvements 
in survival and response rates with selinexor were associated with higher rates of 
adverse events [30].
This work was supported by the project for conceptual development of research 
organisation No 00023736 (Institute of Hematology and Blood Transfusion) from 
the Ministry of Health of the Czech Republic.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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